Procter & Gamble Hygiene & Healthcare Ltd. News and Updates

Name: Latest research reports of Procter & Gamble Hygiene & Healthcare Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Procter & Gamble Hygiene & Healthcare Ltd.
Rating: 3
Author: Motilal Oswal

Keep track of all breaking news on Procter & Gamble Hygiene & Healthcare Ltd. from all sources in a single place.

Load latest

Procter & Gamble Hygiene & Healthcare Ltd.

29 Nov 2019

13204.00

0.06%

Procter & Gamble India sets up Rs 200-crore fund focused on climate

Business Standard

The new fund is in addition to its innovation sourcing fund that the company, the local unit of the world's largest consumer goods firm P&G, had launched last year

Number of MF schemes decreased from 21 to 15 in Mar 2025 qtr

Procter & Gamble India sets up 200 crore environmental sustainability fund

livemint | 28 Nov 2019 1 more

Procter & Gamble Hygiene & Healthcare Ltd.

20 Nov 2019

13204.00

0.06%

Strong comeback after three muted years

Neutral: Procter & Gamble Hygiene &...

Motilal Oswal

20 November 2019 PGHH has maintained its focus on strengthening the brand fundamentals through strategic moves such as innovation, product launches, distribution expansion, and superior communication/execution. Sales increased 20% YoY in FY19, primarily led by the feminine hygiene segment (+24.4% YoY; 70% of sales). Healthcare segment too exhibited a healthy performance (+11.2% YoY), driven by 14% YoY growth in Vicks VapoRub. Under the Whisper brand, PGHH launched Whisper Choice Aloe Vera to tap into the rising fervor for naturals among the Indian consumers. Whisper school program created awareness among five million girls across 40,000 schools about the importance of menstrual hygiene in FY19. Notably, this program has reached 25 million girls since 1995. In Healthcare, the higher penetration for Rubs, new launches (premium lozenge Vicks 3-in-1), distribution expansion and strong advertising helped the segment to grow in double digits in FY19. Interestingly, ad spends were even higher at 12.3% (+180bp YoY) in 1QFY20.

Procter & Gamble Hygiene & Healthcare Ltd. is trading below all available SMAs

Procter & Gamble Hygiene & Healthcare Ltd.

05 Nov 2019

13204.00

0.06%

Procter & Gamble Hygiene and Health Care Q1 profit dips 5% to Rs 136.8 crore, sales up 8%

Business Today

P&G Hygiene and Health Care Q1 results: The company, that operates in the feminine hygiene and healthcare categories with brands such as Whisper, Vicks and Old Spice, saw sales rise by 8 per cent to Rs 852.14 crore in Q1 FY20 as compared to Rs 791.80 crore in Q1 FY19

Procter & Gamble Hygiene & Healthcare Ltd. is trading below all available SMAs

Procter & Gamble Hygiene & Healthcare Ltd.

05 Nov 2019

13204.00

0.06%

Blip in sales growth after four strong quarters; structural levers intact

Neutral: Procter & Gamble Hygiene &...

Target

Motilal Oswal

1QFY20 (ending Jun'19) net sales grew 7.6% YoY to INR8.5b (v/s est. 9.2b). However, EBITDA declined 13.1% YoY to INR1.8b (v/s est. INR2.1b). PBT declined 12.2% YoY to INR1.8b (v/s est. INR2.1b). Adj. PAT was flat YoY at INR1.4b (v/s est. INR1.4b) due to lower corporate taxes. Feminine care business registered strong double-digit growth, while the healthcare business (likely to have been a laggard in 1QFY20) still reportedly grew faster than the market. Gross margins expanded 20bp YoY to 60.4% (v/s est. 59.0%). EBITDA...

Number of MF schemes decreased from 21 to 15 in Mar 2025 qtr

Procter & Gamble Hygiene & Healthcare Ltd.

22 Aug 2019

13204.00

0.06%

Sales momentum intact, but a big miss on margins

Neutral: Procter & Gamble Hygiene &...

Target

Motilal Oswal

22 August 2019 the fourth straight quarter of extremely healthy sales growth. Even adjusted for the GST effect on sanitary napkins (which optically inflates sales but has an adverse effect on operating costs), comparable growth stands healthy at 12% YoY for 4QFY19 and 14% YoY for FY19. EBITDA, however, was down 210bp YoY (off an extremely high base of 4QFY18), but other expenses were up by 330bp YoY. The sharp increase in other expenses (for which no explanations were provided) is surprising, given that it too has come off a very high base (+630bp YoY in 4QFY18). Net sales were up by 20% to INR29.5b. EBITDA declined 3% to INR6.1b, while adj. Margins have remained volatile over the past few years, but sales growth has revived significantly due to distribution expansion and sharp ad spends in the preceding quarters. While the structural growth opportunity in the feminine hygiene segment (~70% of sales) remains very promising, valuations of 52.

Number of FII/FPI investors increased from 137 to 150 in Mar 2025 qtr.

Procter & Gamble Hygiene & Healthcare Ltd.

21 Aug 2019

13204.00

0.06%

Procter & Gamble Hygiene and Health Care profit rises 12% to Rs 419 crore in FY19, sales up 20%

Business Today

During the April-June quarter, the net profit of PGHHCL jumped 36.45 per cent to Rs 60.79 crore as compared to Rs 44.55 crore during the same quarter last year

Number of MF schemes decreased from 21 to 15 in Mar 2025 qtr

Procter & Gamble Hygiene & Healthcare Ltd.

08 May 2019

13204.00

0.06%

P&G; Hygiene's net up 8% in Q3

Business Line

Personal care products manufacturer Procter & Gamble Hygiene and Health Care (P&GHHC) reported an 8 per cent increase in net profit at 90 cro

Number of FII/FPI investors increased from 137 to 150 in Mar 2025 qtr.

Tide-maker P&G; profit up 8% in Q3

Business Line | 08 May 2019

Procter & Gamble Hygiene & Healthcare Ltd.

08 May 2019

13204.00

0.06%

Sales growth momentum sustains; margins below expectations

Neutral: Procter & Gamble Hygiene &...

Target

Motilal Oswal

3QFY19 (June-ending) net sales witnessed third consecutive quarter of strong sales revival at 22.9% YoY to INR7b (v/s est. of INR6.5b). EBITDA was in line at INR1.44b (down 1.9% YoY) and PAT was slightly below expectations at INR903m (v/s est. of INR928m), up 8.3% YoY. Management mentioned that adjusted for GST impact in the base quarter, sales growth was ~15%. Gross margins contracted 630bp YoY to 57.7%, likely due to (a) impact of 10% price cuts taken in Whisper Choice Ultra, and (b) absence of input tax credit under GST for sanitary napkins. Adspend declined off a high base by 270bp YoY...

Procter & Gamble Hygiene & Healthcare Ltd. is trading below all available SMAs

Procter & Gamble Hygiene & Healthcare Ltd.

07 Feb 2019

13204.00

0.06%

Sales momentum sustains; material cut in EPS forecasts on major margin miss

Economy Update: Procter & Gamble Hygiene &...

Motilal Oswal

7 February 2019 which can be attributed to a combination of factors, such as (a) high commodity inflation levels, as also witnessed by peers so far in the Dec18 results, (b) 10% price cuts in and (c) absence of input tax credit under GST for sanitary napkins. EBITDA margin shrank 650bp YoY to 23.4%, led by higher ad spends (+140bp YoY fourth straight quarter of sharp increase YoY), employee cost (+40bp YoY) and other expenses (+10bp YoY). Net sales were up by 18.2% YoY to INR16.1b, EBITDA rose 0.8% YoY to INR4b and PAT grew 5.0% YoY to INR2.6b. Absence of input tax credit and price reduction will have an impact on margins in the subsequent quarters as category growth potential in the feminine hygiene segment (~70% of sales) and potential for market share growth because of its considerable moats and (2) potentially huge margin gains from premiumization over the longer term in feminine hygiene.

Number of FII/FPI investors increased from 137 to 150 in Mar 2025 qtr.

Procter & Gamble Hygiene & Healthcare Ltd.

08 Jan 2019

13204.00

0.06%

Signs of revival after a couple of muted years

Neutral: Procter & Gamble Hygiene &...

Target

Motilal Oswal

8 January 2019 The aggression demonstrated by the PGHH management in recent quarters on increase in ad spends, new launches and price cuts, wherever required. Continued market share gain in Vicks. New product - Vicks Baby Rub, launched in FY18 is reportedly doing very well. While valuations of 51.7x FY20 EPS implies that near-term upside is limited, category growth potential in the Feminine Hygiene segment (~67% of sales) and potential for market share growth because of its considerable moats, and (2) Potentially huge margin gains from premiumization in Feminine Hygiene over the longer term. Increasing pace of distribution expansion, continuing strong pace of category development efforts in schools to boost awareness and growth, rising ad spends after a lull in preceding years, healthy pipeline of new products and willingness to take price cuts whenever required to boost growth are all encouraging developments that should aid rapid growth for the company over the long term.